Thomas W. Dubensky Jr., Ph.D., has served as our Chief Scientific Officer since September 2011. From 2009 to 2011, Dr. Dubensky served as Chief Scientific Officer of Immune Design where he was responsible for overseeing the development of immune therapies based on proprietary molecularly defined adjuvants and dendritic cell targeting vaccine platforms. Prior to this, in 2007 he co-founded and served as Chief Scientific Officer of Anza Therapeutics, a biotechnology company that was spun out from Cerus Corporation where he had served as Vice President of Research for the five years prior. During this time, Dr. Dubensky helped to develop vaccine platforms based on attenuated strains of listeria monocytogenes, which serves as the technology basis for Aduro’s LADD platform. Earlier in his career, Dr. Dubensky developed vaccine platforms based on alphaviruses, adenoviruses, retroviruses/lentiviruses and plasmid DNA at a number of biotechnology companies, including Viagene, Chiron Corporation and Onyx Pharmaceuticals. Dr. Dubensky has co-authored more than 70 scientific papers and is an inventor on 35 issued U.S. patents with multiple pending applications. Dr. Dubensky received his B.A. in Bacteriology and Immunology from the University of California, Berkeley, and his Ph.D. at the University of Colorado Health Sciences Center. He conducted his post-doctoral fellowship at Harvard Medical School in the Department of Pathology.  

 Immune Design and therapies